Technical Analysis for KMPH - KemPharm, Inc.

Grade Last Price % Change Price Change
grade C 4.975 2.58% 0.13
KMPH closed up 2.58 percent on Tuesday, September 18, 2018, on approximately normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Up Down
See historical KMPH trend table...

Date Alert Name Type % Chg
Sep 18 Crossed Above 20 DMA Bullish 0.00%
Sep 18 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Sep 18 Bollinger Band Squeeze Range Contraction 0.00%
Sep 18 BB Squeeze Started Range Contraction 0.00%
Sep 17 Fell Below 20 DMA Bearish 2.58%
Sep 17 Outside Day Range Expansion 2.58%
Sep 17 Upper Bollinger Band Touch Strength 2.58%
Sep 14 Pocket Pivot Bullish Swing Setup -3.40%
Sep 12 Crossed Above 50 DMA Bullish -3.40%
Sep 12 180 Bullish Setup Bullish Swing Setup -3.40%

Older signals for KMPH ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Read My Charts!
Configure default chart indicators
Basic chart:

Profile
KemPharm is a specialty pharmaceutical company focused on the discovery and development of NME prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology. KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high needs areas of pain, ADHD and other CNS disorders.
Is KMPH a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 1 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Sep 18 KemPharm Announces Positive Data - Street Wants To See A Partner
Sep 18 Senate passes opioid crisis bill
Sep 17 KemPharm on go with U.S. filing for KP415 after intranasal HAP study; shares up 8% premarket
Sep 17 KemPharm Announces Positive Topline Results from Intranasal Human Abuse Potential Trial of KP415 Prodrug
Sep 12 KemPharm Posts Positive Top-Line Results on KP415 Prodrug
Sep 11 KemPharm prodrug SDX shows lower abuse potential in study
Sep 11 KemPharm Announces Positive Topline Results from Oral Human Abuse Potential Trial of KP415 Prodrug
Sep 7 Senate vote approaches on bill to combat opioid crisis
Sep 5 KemPharm to Present at Two Healthcare Investor Conferences During September 2018
Aug 31 FDA rejects Sunovion's dasotraline for ADHD
See more KMPH news...
Indicators
Indicator Value
52 Week High 8.4
52 Week Low 3.44
Average Volume 124,252
200-Day Moving Average 5.5221
50-Day Moving Average 4.7476
20-Day Moving Average 4.939
10-Day Moving Average 5.0005
Average True Range 0.3222
ADX 11.77
+DI 18.3232
-DI 21.7561
Chandelier Exit (Long, 3 ATRs ) 4.5034
Chandelier Exit (Short, 3 ATRs ) 5.3666
Upper Bollinger Band 5.3689
Lower Bollinger Band 4.5091
Percent B (%b) 0.54
BandWidth 17.408382
MACD Line 0.0576
MACD Signal Line 0.0551
MACD Histogram 0.0024
Fundamentals Value
Market Cap 72.92 Million
Num Shares 14.7 Million
EPS -3.10
Price-to-Earnings (P/E) Ratio -1.60
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.35
Resistance 3 (R3) 5.33 5.19 5.29
Resistance 2 (R2) 5.19 5.10 5.20 5.27
Resistance 1 (R1) 5.08 5.04 5.14 5.10 5.25
Pivot Point 4.94 4.94 4.97 4.95 4.94
Support 1 (S1) 4.83 4.85 4.89 4.85 4.70
Support 2 (S2) 4.69 4.79 4.70 4.68
Support 3 (S3) 4.58 4.69 4.66
Support 4 (S4) 4.60